13.52

0.22% -0.02

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $13.52, with a volume of 94,595. It is down -0.22% in the last 24 hours and down -2.95% over the past month. Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Previous Close:

$13.50

Open:

$13.46

24h Volume:

94,595

Relative Volume:

0.64

Market Cap:

$676.78M

Revenue:

Net Income/Loss:

$-119.67M

P/E Ratio:

-9.5853

EPS:

-1.4105

Net Cash Flow:

$-97.30M

1W Performance:

-3.51%

1M Performance:

-2.95%

6M Performance:

+4.02%

1Y Performance:

+62.09%

1-Day Range:

$13.33

$13.70

1-Week Range:

$12.57

$13.96

52-Week Range:

$5.85

$16.91

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER ROAD, RADNOR

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLYS's Discussions on Twitter

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com

Nov 04, 2024

Nov 03, 2024

Objective long/short (MLYS) Report - Stock Traders Daily

Nov 03, 2024

Nov 02, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN

Nov 02, 2024

Oct 31, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024

Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times

Oct 30, 2024

Oct 29, 2024

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN

Oct 29, 2024

Oct 24, 2024

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo

Oct 24, 2024

Oct 23, 2024

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Oct 23, 2024

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance

Oct 20, 2024

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com

Oct 16, 2024

Oct 15, 2024